ECP 2022 Final Programme

Poster Sessions a Tuesday 103 ECP 2022 Basel Tuesday, 6 Sept PS-15 005 KRAS mutations in 1355 Italian patients with lung adenocarcinoma Panagiotis Paliogiannis, Italy R. Lobrano, M. Colombino, M. Sini, A. Fara, M. Fedeli, G. Palmieri, A. Cossu 006 Increased expression of the CST2 gene is associated with lymphatic dissemination of prostate cancer Vladislav Pavlov, Russia E. Pudova, A. Kobelyatskaya, A. Snezhkina, I. Katunina, K. Nyushko, D. Kalinin, K. Sergey, M. Fedorova, G. Krasnov, A. Kudryavtseva 007 NTRK fusion genes in cholangiocarci- noma Tiina Vesterinen, Finland S. Boyd, S. Kytölä, J. Arola 008 Analysis of PINK1 immunoexpression in primary lung adenocarcinomas revealed a group of patients with a poorer prognosis Ivan Fernandez Vega, Spain D. Corte-Torres, A. Vallina, J. Celis Pinto, M. Rubiera, S. Fernández Menéndez, K. Piña Batista 009 Analysis of p62 immunoexpression in metastatic samples of lung adenocarcino- mas to the brain revealed a group of patients with a poorer prognosis Ivan Fernandez Vega, Spain D. Corte-Torres, A. Vallina, J. Celis Pinto, M. Rubiera, S. Fernández Menéndez, K. Piña Batista 010 NGS-based molecular profiling and liquid biopsies: an assessment of pathologists and oncologists knowledge and attitudes Nabil Dorkhom, The Netherlands D. Middleton, T. Abair, A. Vingiani, G. Pruneri 011 Study of gene expression by in situ hybridization in tissues with prostate adenocarcinoma routinely processed Ines Benedetti, Colombia L. Barrios 012 Arylsulfatase B gene expression profile in colorectal cancer Zsolt Kovacs, Romania I. Jung, R. Stefan-Van Staden, A. Patrichi, S. Gurzu 013 The spectrum of gene fusions in primary epithelial ovarian tumours identified by panel RNA NGS approach Ivana Stružinská, Czech Republic M. Flídrová, J. Galko, R. Jakša, K. Němejcová, M. Bártů, Q. Bui, J. Hojný, P. Dundr 014 Development of a murine-model of oral carcinogenesis: a rapid tool for biomarker and anti-tumour drug discovery Sofia Ali Syed, Pakistan M. Qureshi, S. Khan, R. Kumar, Y. Shafique, B. Khan, J. Safdar 015 The effect of mitochondrial energy metabolism modulators on cytotoxicity of cisplatin and pemetrexed in mesothelioma Suncana Sikiric, Croatia A. Šepac, F. Sedlić, S. Seiwerth 016 The clinical significance of epigenetic and RNAPII variabilities occurring in clear cell renal cell carcinoma as a potential prognostic marker Tibor Pankotai, Hungary N. Ördög, B. Borsos, H. Majoros, Z. Ujfaludi, L. Kuthi, G. Pankotai-Bodo, S. Bankó, F. Sükösd 017 Long non-coding RNA H19 expression in rectal cancer and therapy response Katarina Eric, Serbia M. Miladinov, S. Dragicevic, J. Rosic, Z. Krivokapic, K. Zeljic 019 BRG1-deficient non-small cell lung carcinomas. Clinicopathologic character- istics and correlation with SMARCA4 mutations Víctor Pedrero, Spain V. Cristóbal Redondo, A. Francia García- Calvo, C. Alenda González, F. Aranda López